QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
QQQ   414.65 (-2.07%)
AAPL   165.00 (-1.22%)
MSFT   399.12 (-1.27%)
META   481.07 (-4.13%)
GOOGL   154.09 (-1.23%)
AMZN   174.63 (-2.56%)
TSLA   147.05 (-1.92%)
NVDA   762.00 (-10.00%)
AMD   146.64 (-5.44%)
NIO   3.80 (-5.00%)
BABA   69.07 (+0.28%)
T   16.51 (+1.10%)
F   12.14 (+0.66%)
MU   106.77 (-4.61%)
GE   148.06 (-3.19%)
CGC   7.93 (+1.28%)
DIS   112.61 (+0.16%)
AMC   3.16 (+8.22%)
PFE   26.00 (+2.40%)
PYPL   62.31 (+0.34%)
XOM   119.88 (+1.15%)
Free Trial
NASDAQ:BLU

BELLUS Health (BLU) Stock Price, News & Analysis

→ Will this $2 AI stock double overnight? (From Behind the Markets) (Ad)
Free BLU Stock Alerts
Notice: This company has been marked as potentially delisted and may not be actively trading.
Compare
Today's Range
$14.74
▼
$14.75
50-Day Range
$14.42
▼
$14.75
52-Week Range
$6.38
▼
$14.76
Volume
3.45 million shs
Average Volume
3.08 million shs
Market Capitalization
$1.87 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Stock Analysis
Stock Analysis
BLU stock logo

About BELLUS Health Stock (NASDAQ:BLU)

BELLUS Health Inc., a clinical-stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. BELLUS Health Inc. was incorporated in 1993 and is based in Laval, Canada. As of June 28, 2023, BELLUS Health Inc. operates as a subsidiary of GSK plc.

BLU Stock News Headlines

March 21, 2024 | msn.com
Deal reached between Dignity Health, Arizona Blue Cross Blue Shield
March 4, 2024 | msn.com
The effects of 'blue light' on human health are still unclear, says panel
April 19, 2024 | Stansberry Research (Ad)
Strange new buyer driving up gold
One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."
January 4, 2024 | msn.com
Glowing blue waves off Orange County coast make for thrilling start to New Year
December 21, 2023 | markets.businessinsider.com
Analysts Are Bullish on These Healthcare Stocks: Bluebird Bio (BLUE), United Therapeutics (UTHR)
September 21, 2023 | forbes.com
CBD Dosage: How Much Should You Take?
June 28, 2023 | fool.com
Bellus Health (NASDAQ: BLU)
June 27, 2023 | msn.com
These Canadian Biotech Stocks Are Quietly Changing the Face of Healthcare
April 19, 2024 | Stansberry Research (Ad)
Strange new buyer driving up gold
One Wall Street trader just made a big new gold prediction: "Pay attention to physical demand for gold... the interest seen over the last week has been unprecedented."
June 25, 2023 | finance.yahoo.com
BLU.TO - BELLUS Health Inc.
June 17, 2023 | markets.businessinsider.com
BTIG Reaffirms Their Hold Rating on BELLUS Health (BLU)
May 10, 2023 | ca.finance.yahoo.com
TSX Stocks in the Healthcare Industry: Which Ones Are Worth Your Money?
May 10, 2023 | finance.yahoo.com
Should You Buy Bellus Health (BLU) After Golden Cross?
May 2, 2023 | theglobeandmail.com
Closing Bell: Bellus Health Inc up on Tuesday (BLU)
April 26, 2023 | theglobeandmail.com
BELLUS Health: Top 25 Performing Stocks Year-to-Date on Toronto Stock Exchange (BLU)
April 26, 2023 | finance.yahoo.com
BELLUS Health Announces Meeting Updates
April 21, 2023 | benzinga.com
Moore Kuehn Encourages BLU, STSA, RXDX, STSA, and CHRA Investors to Contact Law Firm
April 19, 2023 | finance.yahoo.com
Bellus Health (BLU) Stock Up 99% on $2B Buyout Offer From GSK
April 19, 2023 | theglobeandmail.com
GSK’s $2-billion purchase of Bellus delivers second big exit for Montreal’s Bellini family
April 19, 2023 | reuters.com
GSK bets $2 bln on Bellus cough drug to soothe pipeline fears
April 18, 2023 | markets.businessinsider.com
LifeSci Capital Reaffirms Their Hold Rating on BELLUS Health (BLU)
April 18, 2023 | theglobeandmail.com
GSK signs deal to buy Canadian drug developer Bellus Health for US$2 billion
April 18, 2023 | finance.yahoo.com
Bellus Health Soars 99% As GSK Joins Buyout Bonanza With $2 Billion Deal
April 18, 2023 | cnbc.com
Stocks making the biggest moves midday: Southwest Airlines, Goldman Sachs, Bellus Health and more
April 18, 2023 | bizjournals.com
GSK to buy Canadian biopharm firm Bellus Health for $2 billion
April 18, 2023 | finance.yahoo.com
Bellus Health Soars 98% As GSK Joins Buyout Bonanza With $2 Billion Deal
April 18, 2023 | finance.yahoo.com
Why BELLUS Health Stock Is Rocketing Higher Today
See More Headlines
Receive BLU Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for BELLUS Health and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/10/2021
Today
4/19/2024
Fiscal Year End
12/31/2024
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:BLU
CUSIP
N/A
CIK
1259942
Web
www.bellushealth.com
Phone
(450) 680-4500
Fax
45-0680-4501
Employees
74
Year Founded
N/A

Profitability

EPS (Most Recent Fiscal Year)
($0.72)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-76,080,000.00
Net Margins
-578,586.63%
Pretax Margin
-578,226.56%
Return on Equity
-24.27%
Return on Assets
-23.14%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
33.42
Quick Ratio
33.42

Sales & Book Value

Annual Sales
$15,000.00
Price / Sales
124,613.93
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$3.09 per share
Price / Book
4.77

Miscellaneous

Outstanding Shares
126,812,000
Free Float
96,162,000
Market Cap
$1.87 billion
Optionable
Not Optionable
Beta
0.19
13 Stocks Institutional Investors Won't Stop Buying Cover
13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Mr. Roberto Francesco BelliniMr. Roberto Francesco Bellini (Age 43)
    Pres, CEO & Director
    Comp: $790.35k
  • Mr. Ramzi Benamar (Age 50)
    Chief Financial Officer
    Comp: $650.48k
  • Dr. Andreas Orfanos FFPM (Age 64)
    M.B.B.Ch, MBA, Chief Operating Officer
    Comp: $417.58k
  • Dr. Denis Garceau Ph.D. (Age 66)
    Chief Scientific Officer
    Comp: $496.56k
  • Dr. Catherine M. Bonuccelli M.D. (Age 65)
    Chief Medical Officer
    Comp: $741.66k
  • Mr. Daniel Matthews
    Director of Investor Relations & Communications
  • Mr. Tony Matzouranis (Age 50)
    Chief Bus. Officer
  • Mr. Sebastien Roy (Age 47)
    Corp. Sec.

Key Competitors

View All Competitors

BLU Stock Analysis - Frequently Asked Questions

How were BELLUS Health's earnings last quarter?

BELLUS Health Inc. (NASDAQ:BLU) announced its earnings results on Wednesday, November, 10th. The company reported ($0.29) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.22) by $0.07. BELLUS Health had a negative net margin of 578,586.63% and a negative trailing twelve-month return on equity of 24.27%.

What other stocks do shareholders of BELLUS Health own?

Based on aggregate information from My MarketBeat watchlists, some companies that other BELLUS Health investors own include Big Lots (BIG), Party City Holdco (PRTY), Washington Prime Group (WPG), Akorn (AKRXQ), Akers Biosciences (AKER), Akebia Therapeutics (AKBA), Adamis Pharmaceuticals (ADMP), ADMA Biologics (ADMA) and Acasti Pharma (ACST).

This page (NASDAQ:BLU) was last updated on 4/19/2024 by MarketBeat.com Staff

From Our Partners
The Best AI Stock to Own in the World Today is Trading for Just $25
Banyan Hill Publishing
Tiny Biotech Stock Wins $75 Billion Patent
Behind the Markets
Biden’s $374B Giveaway Into This Sector
DTI
He Is Giving Away Bitcoin
Crypto Swap Profits
The #1 Crypto for 2024
InvestorPlace
SHOCKING Crypto Leak…
Crypto 101 Media
How Biden has already won 2024
Porter & Company
Urgent alert: open this for a huge profit potential
Timothy Sykes